These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 22336262)

  • 1. Acute and short-term effect of an extra dose of formoterol in COPD patients.
    Studart FS; Izbicki M; Nery LE; Oliveira LV; Donner CF; Jardim JR; Nascimento OA
    Respir Med; 2012 Jun; 106(6):853-60. PubMed ID: 22336262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
    Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD.
    Derom E; Strandgården K; Schelfhout V; Borgström L; Pauwels R
    Respir Med; 2007 Sep; 101(9):1931-41. PubMed ID: 17544264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bronchodilator effects of indacaterol and formoterol in patients with COPD.
    Beier J; Beeh KM; Brookman L; Peachey G; Hmissi A; Pascoe S
    Pulm Pharmacol Ther; 2009 Dec; 22(6):492-6. PubMed ID: 19465142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial.
    Bölükbas S; Eberlein M; Eckhoff J; Schirren J
    Eur J Cardiothorac Surg; 2011 Jun; 39(6):995-1000. PubMed ID: 20970351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.
    van Noord JA; Aumann JL; Janssens E; Smeets JJ; Verhaert J; Disse B; Mueller A; Cornelissen PJ
    Eur Respir J; 2005 Aug; 26(2):214-22. PubMed ID: 16055868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
    Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
    Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A; Szalai Z; Pullerits T; Radeczky E
    Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.
    Tashkin DP; Littner M; Andrews CP; Tomlinson L; Rinehart M; Denis-Mize K
    Respir Med; 2008 Apr; 102(4):479-87. PubMed ID: 18258423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled formoterol versus ipratropium bromide in chronic obstructive pulmonary disease.
    Chhabra SK; Vijayan VK; Vasu T
    Indian J Chest Dis Allied Sci; 2006; 48(2):97-102. PubMed ID: 16696522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility.
    Bouros D; Kottakis J; Le Gros V; Overend T; Della Cioppa G; Siafakas N
    Curr Med Res Opin; 2004 May; 20(5):581-6. PubMed ID: 15140323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.
    Rosenkranz B; Rouzier R; Kruse M; Dobson C; Ayre G; Horowitz A; Fitoussi S
    Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there any difference between effects of ipratropium bromide and formoterol on exercise capacity in moderate COPD patients?
    Akkoca Yildiz O; Onen ZP; Demir G; Eriş Gülbay B; Saryal S; Karabiyikoğlu G
    Tuberk Toraks; 2006; 54(2):105-13. PubMed ID: 16924565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formoterol by pressurized metered-dose aerosol or dry powder on airway obstruction and lung hyperinflation in partially reversible COPD.
    Brusasco V; Canonica GW; Dal Negro R; Scano G; Paggiaro P; Fabbri LM; Barisione G; D'Amato G; Varoli G; Baroffio M; Milanese M; Mereu C; Crimi E
    J Aerosol Med Pulm Drug Deliv; 2011 Oct; 24(5):235-43. PubMed ID: 21689019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of formoterol on exercise tolerance in severely disabled patients with COPD.
    Neder JA; Fuld JP; Overend T; Thirlwell J; Carter R; Stevenson R; Ward SA
    Respir Med; 2007 Oct; 101(10):2056-64. PubMed ID: 17658249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease.
    Zhong N; Zheng J; Wen F; Yang L; Chen P; Xiu Q; Yao W; Sun T; Zhao Z; Shen H; Shi Y; Lin J; Li Q
    Curr Med Res Opin; 2012 Feb; 28(2):257-65. PubMed ID: 22046961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
    Kuna P; Jenkins M; O'Brien CD; Fahy WA
    Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study.
    Vogelmeier C; Kardos P; Harari S; Gans SJ; Stenglein S; Thirlwell J
    Respir Med; 2008 Nov; 102(11):1511-20. PubMed ID: 18804362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.